公开(公告)号：US20210024650A1

公开(公告)日：2021-01-28

申请号：US16939536

申请日：2020-07-27

申请人： ABL Bio Inc. ,  YUHAN CORPORATION

发明人： Hyejin CHUNG ,  Yeryoung Yong ,  Kyeongsu Park ,  Eunyoung Park ,  Ui-Jung Jung ,  Yangsoon Lee ,  Eunjung Kim ,  Yong-Gyu Son ,  Wonjun Son ,  Seawon Ahn ,  Donghoon Yeom ,  Chanmoo Lee ,  Junghyeon Hong ,  Moo Young Song ,  Eun-Jung Lee ,  Na Rae Lee ,  Young Bong Park ,  Eun-Jung Lee ,  Taewang Kim

IPC分类号： C07K16/32 ,  C07K16/28 ,  A61P35/00

摘要： Provided are an anti-4-1BB/anti-HER2 bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

公开(公告)号：US10858353B2

公开(公告)日：2020-12-08

申请号：US16633695

申请日：2018-07-25

申请人： Yuhan Corporation

发明人： Sang-Ho Oh ,  Ja-Heouk Khoo ,  Jong-Chul Lim ,  Doo-Byung Lee ,  Jung-Ae Lee ,  Jun-Sup Lee ,  Hyun Ju ,  Woo-Seob Shin ,  Sang-Seol Jeon

IPC分类号： C07D413/14 ,  C07D265/32 ,  C07D403/10

摘要： The present invention provides a novel process for preparing an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors. And also, the present invention provides novel intermediates useful for said process and processes for preparing the same.

公开(公告)号：US20180072705A1

公开(公告)日：2018-03-15

申请号：US15813741

申请日：2017-11-15

申请人： Yuhan Corporation

发明人： Hyun-Joo LEE ,  Dong-Hoon KIM ,  Tae-Kyun KIM ,  Young-Ae YOON ,  Jae-Young SIM ,  Myung-Hun CHA ,  Eun-Jung JUNG ,  Kyoung-Kyu AHN ,  Tai-Au LEE

IPC分类号： C07D403/04 ,  C07D417/04 ,  C07D413/14 ,  C07D401/04 ,  C07D413/04

CPC分类号： C07D403/04 ,  C07D401/04 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04

摘要： The present invention provides a diaminopyrimidine derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, a pharmaceutical composition comprising the same, and a use thereof. The diaminopyrimidine derivative or its pharmaceutically acceptable salt functions as a 5-HT4 receptor agonist, and therefore can be usefully applied for preventing or treating dysfunction in gastrointestinal motility, one of the gastrointestinal diseases, such as gastroesophageal reflux disease (GERD), constipation, irritable bowel syndrome (IBS), dyspepsia, post-operative ileus, delayed gastric emptying, gastroparesis, intestinal pseudo-obstruction, drug-induced delayed transit, or diabetic gastric atony.

公开(公告)号：US09850227B2

公开(公告)日：2017-12-26

申请号：US14001475

申请日：2012-02-24

申请人： Hyun-Joo Lee ,  Dong-Hoon Kim ,  Tae-Kyun Kim ,  Young-Ae Yoon ,  Jae-Young Sim ,  Myung-Hun Cha ,  Eun-Jung Jung ,  Kyoung-Kyu Ahn ,  Tai-Au Lee

发明人： Hyun-Joo Lee ,  Dong-Hoon Kim ,  Tae-Kyun Kim ,  Young-Ae Yoon ,  Jae-Young Sim ,  Myung-Hun Cha ,  Eun-Jung Jung ,  Kyoung-Kyu Ahn ,  Tai-Au Lee

IPC分类号： A01N43/00 ,  A01N43/46 ,  A61K31/55 ,  C07D403/04 ,  C07D401/04 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04

CPC分类号： C07D403/04 ,  C07D401/04 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04

摘要： The present invention provides a diaminopyrimidine derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, a pharmaceutical composition comprising the same, and a use thereof. The diaminopyrimidine derivative or its pharmaceutically acceptable salt functions as a 5-HT4 receptor agonist, and therefore can be usefully applied for preventing or treating dysfunction in gastrointestinal motility, one of the gastrointestinal diseases, such as gastroesophageal reflux disease (GERD), constipation, irritable bowel syndrome (IBS), dyspepsia, post-operative ileus, delayed gastric emptying, gastroparesis, intestinal pseudo-obstruction, drug-induced delayed transit, or diabetic gastric atony.

公开(公告)号：US09663495B2

公开(公告)日：2017-05-30

申请号：US14786837

申请日：2014-04-22

申请人： YUHAN CORPORATION

发明人： Tae-Dong Han ,  Eun-Hye Jung ,  Chung-Ho Yi ,  Byoung-Moon Lee ,  Yoo-Hoi Park ,  Dong-Hoon Lee ,  Jong-Ho Kang ,  Na-Yeon Yang ,  Do-Hoon Kim ,  Kwan-Hoon Hyun ,  Kaap-Joo Park ,  Chun-Ho Lee ,  Su-Youn Nam

IPC分类号： C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07C403/10 ,  C07C403/14 ,  C07D405/04 ,  C07D405/06 ,  C07D413/14 ,  C07D249/12 ,  C07D403/10 ,  C07D403/14 ,  C07D405/14

CPC分类号： C07D401/14 ,  C07D249/12 ,  C07D401/10 ,  C07D403/04 ,  C07D403/10 ,  C07D403/14 ,  C07D405/04 ,  C07D405/06 ,  C07D405/14 ,  C07D413/14

摘要： Provided is a triazolone derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The triazolone derivative or its pharmaceutically acceptable salt can effectively activate GPR119; and therefore be usefully applied for preventing or treating diabetes mellitus.

公开(公告)号：US20160102076A1

公开(公告)日：2016-04-14

申请号：US14881930

申请日：2015-10-13

申请人： Yuhan Corporation

发明人： Byung-Chul Suh ,  Paresh Devidas Salgaonkar ,  Jaekyoo Lee ,  Jong Sung Koh ,  Ho-Juhn Song ,  In Yong Lee ,  Jaesang Lee ,  Dong Sik Jung ,  Jung-Ho Kim ,  Se-Won Kim

IPC分类号： C07D403/04 ,  C07D409/14 ,  C07D413/14 ,  C07D403/14

CPC分类号： C07D403/04 ,  A61K31/506 ,  C07D403/14 ,  C07D409/14 ,  C07D413/14

摘要： The present invention provides a new group of protein kinase inhibitors, aminopyrimidine derivatives, and pharmaceutically acceptable salts thereof that are useful for treating cell proliferative disease and disorder such as cancer and immune disease. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefore. The invention also provides useful intermediates generated during the syntheses of the aminopyrimidine derivatives.

摘要翻译： 本发明提供了一组可用于治疗细胞增殖性疾病和病症如癌症和免疫疾病的蛋白激酶抑制剂，氨基嘧啶衍生物及其药学上可接受的盐。 本发明提供了合成和施用蛋白激酶抑制剂化合物的方法。 本发明还提供了包含至少一种蛋白激酶抑制剂化合物以及药学上可接受的载体，稀释剂或赋形剂的药物制剂。 本发明还提供了在合成氨基嘧啶衍生物期间产生的有用的中间体。

公开(公告)号：US08663658B2

公开(公告)日：2014-03-04

申请号：US12520037

申请日：2007-12-21

申请人： Young-Joon Park ,  Chang-Keun Hyun

发明人： Young-Joon Park ,  Chang-Keun Hyun

IPC分类号： A61K31/506 ,  A61K47/48

CPC分类号： A61K9/1635 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/1652 ,  A61K31/506

摘要： The present invention provides a solid dispersion in which revaprazan particles are surface-modified with a water-soluble polymer, a water-soluble saccharide, a surfactant, or a mixture thereof and a process for preparing the same. The present invention also provides a pharmaceutical composition containing the solid dispersion and a process for preparing the pharmaceutical composition.

摘要翻译： 本发明提供了一种固体分散体，其中雷帕拉坦颗粒用水溶性聚合物，水溶性糖，表面活性剂或其混合物进行表面改性，以及其制备方法。 本发明还提供含有固体分散体的药物组合物和制备该药物组合物的方法。

公开(公告)号：US08476432B2

公开(公告)日：2013-07-02

申请号：US13806626

申请日：2011-06-30

申请人： Hyun Ju ,  Sang-Sun Joung ,  Hyun-Jik Yi ,  Ja-Heouk Khoo ,  Jong-Chul Lim ,  Jae-Gyu Kim

发明人： Hyun Ju ,  Sang-Sun Joung ,  Hyun-Jik Yi ,  Ja-Heouk Khoo ,  Jong-Chul Lim ,  Jae-Gyu Kim

IPC分类号： C07D239/42 ,  C07D215/12 ,  C07D405/06 ,  C07D209/10 ,  C07D257/04

CPC分类号： C07D239/69 ,  A61K31/443 ,  C07D209/18 ,  C07D209/24 ,  C07D215/14 ,  C07D239/42 ,  C07D405/06 ,  C07D405/12

摘要： The present invention provides an improved process for preparing HMG-CoA reductase inhibitors such as rosuvastatin calcium, fluvastatin sodium, and pitavastatin calcium under a mild condition, using a novel amide-bond-containing compound having R2—N—O—R1 moiety as a key intermediate. And also, the present invention provides the novel compound, an intermediate useful for the preparation thereof, and a process for the preparation thereof.

摘要翻译： 本发明提供使用具有R2-NO-R1部分作为关键中间体的新型含酰胺键的化合物，在温和条件下制备HMG-CoA还原酶抑制剂如瑞舒伐他汀钙，氟伐他汀钠和匹伐他汀钙的改进方法 。 而且，本发明还提供了新型化合物，可用于其制备的中间体及其制备方法。

公开(公告)号：US20100069430A1

公开(公告)日：2010-03-18

申请号：US12613763

申请日：2009-11-06

申请人： Jae-Gyu KIM ,  Byung-Nak Ahn ,  Hyouk-Woo Lee ,  Suk-Won Yoon ,  Young-Ae Yoon ,  Dong-Hoon Kim ,  Chan-Sun Park ,  Seok-Hee Han ,  Myung-Hun Cha ,  Heui-II Kang ,  Sun-Young Jang

发明人： Jae-Gyu KIM ,  Byung-Nak Ahn ,  Hyouk-Woo Lee ,  Suk-Won Yoon ,  Young-Ae Yoon ,  Dong-Hoon Kim ,  Chan-Sun Park ,  Seok-Hee Han ,  Myung-Hun Cha ,  Heui-II Kang ,  Sun-Young Jang

IPC分类号： A61K31/437 ,  C07D471/04 ,  A61P1/04

CPC分类号： C07D471/04

摘要： The present invention provides novel pyrrolo[2,3-c]pyridine derivatives or pharmaceutically acceptable salts thereof, processes for the preparation thereof, and compositions comprising the same. The pyrrolo[2,3-c]pyridine derivatives or pharmaceutically acceptable salts thereof of the present invention have excellent proton pump inhibition effects and possess the ability to attain a reversible proton pump inhibitory effect.

摘要翻译： 本发明提供新的吡咯并[2,3-c]吡啶衍生物或其药学上可接受的盐，其制备方法和包含其的组合物。 本发明的吡咯并[2,3-c]吡啶衍生物或其药学上可接受的盐具有优异的质子泵抑制作用，具有获得可逆质子泵抑制作用的能力。

公开(公告)号：US20100041688A1

公开(公告)日：2010-02-18

申请号：US12520037

申请日：2007-12-21

申请人： Young-Joon Park ,  Chang-Keun Hyun

发明人： Young-Joon Park ,  Chang-Keun Hyun

IPC分类号： A61K31/506 ,  A61K47/48

CPC分类号： A61K9/1635 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/1652 ,  A61K31/506

摘要： The present invention provides a solid dispersion in which revaprazan particles are surface-modified with a water-soluble polymer, a water-soluble saccharide, a surfactant, or a mixture thereof and a process for preparing the same. The present invention also provides a pharmaceutical composition containing the solid dispersion and a process for preparing the pharmaceutical composition.

摘要翻译： 本发明提供了一种固体分散体，其中雷帕拉坦颗粒用水溶性聚合物，水溶性糖，表面活性剂或其混合物进行表面改性，以及其制备方法。 本发明还提供含有固体分散体的药物组合物和制备该药物组合物的方法。